Trial reportJournal of the International AIDS Society2023
A decision support tool has similar high PrEP uptake and increases early PrEP persistence in adolescent girls and young women in South Africa: results from a randomized controlled trial.
Trial report in Journal of the International AIDS Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 20 citations in OpenAlex.
- Article
- Preferences for mHealth Features to Support Engagement in the HIV Preexposure Prophylaxis Cascade Among Men Who Have Sex With Men in Peru: Cross-Sectional Online Survey.JMIR public health and surveillance · 2026Article
- Person-centered choice and mHealth support for same-day delivery of long-acting injectable cabotegravir (ImPrEP CAB Brasil): a prospective, open-label, multicenter, quasi-experimental implementation study.Lancet regional health. Americas · 2026Article
- Identifying Implementation Gaps in the HIV Prevention Cascade among Peruvian Men Who Have Sex with Men.AIDS and behavior · 2026Article
- Integrating PrEP and Sexual Reproductive Health Services for Adolescent Girls and Young Women in South Africa: A Scoping Review.AIDS and behavior · 2026Review
- Estimated benefits of providing on-demand pre-exposure prophylaxis options for cisgender women in South Africa: A modeling study.PloS one · 2026Article
- Exploring HIV prevention preferences among key populations in Uganda: A qualitative study.PloS one · 2026Article
- '…it helps me to be able to do the right thing …': pilot of a waiting area chatbot to enhance self-assessment of HIV vulnerability and motivation for PrEP use in Nigeria.BMJ digital health & AI · 2026Article
- Supporting Oral and Long-Acting HIV Preexposure Prophylaxis Decision-Making Among Pregnant Women (MyChoice Intervention): Protocol for 2 Pilot Randomized Controlled Trials.JMIR research protocols · 2025Article
- Shades of Contemplation: HIV Pre-Exposure Prophylaxis Decision-Making among Young Women in South Africa.AIDS and behavior · 2025Article
- Masibambane (Let Us Work Together), Ladies Chat: Pilot Evaluation of an Online, Gender-Enhanced, Group-Interactive Workshop to Promote Oral PrEP to Young South African Women.AIDS and behavior · 2025Article
- Postpartum women's prospective acceptability of long-acting HIV prevention approaches in Kenya: a qualitative study.BMC health services research · 2025Article
- Motivations for Starting and Stopping PrEP: Experiences of Adolescent Girls and Young Women in the HPTN 082 Trial.AIDS and behavior · 2025Article
- Measuring Pre-Exposure Prophylaxis (PrEP) Stigma Among Adolescent Girls and Young Women in Western Kenya: Scale Development, Validation, and Associations with PrEP Adherence.AIDS patient care and STDs · 2025Article
- Mobile Health Intervention Tools Promoting HIV Pre-Exposure Prophylaxis Among Adolescent Girls and Young Women in Sub-Saharan Africa: Scoping Review.JMIR mHealth and uHealth · 2025Article
- Long-acting pre-exposure prophylaxis preferences among pregnant and postpartum women in Kenya: results from a discrete choice experiment.AJOG global reports · 2025Article
- Measuring the performance of computer vision artificial intelligence to interpret images of HIV self-testing results.Frontiers in public health · 2024Article
- PrEParing for choice in a new era of HIV prevention.The lancet. HIV · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionAfrican adolescent girls and young women (AGYW) have high rates of HIV acquisition and are a priority population for HIV pre-exposure prophylaxis (PrEP). PrEP implementation has been limited by AGYW's low perceived HIV risk and provider demands. A decision support tool (DST) with information about PrEP could improve clients' risk perception, knowledge about PrEP, informed decision-making and motivation to use PrEP based on their risk, facilitating PrEP delivery in primary healthcare (PHC) clinics.
methodsWe designed MyPrEP, a client-facing DST about PrEP and HIV prevention, with youth-friendly information and images. The impact of the MyPrEP tool was assessed among HIV-negative women aged 18-25 years presenting to a PHC clinic in Johannesburg, South Africa from March 2019 to 2020. AGYW were randomized by day to the DST or a general health website as the control condition. A clinician blinded to DST versus control allocation provided standard of care counselling about PrEP, offered PrEP, administered a questionnaire and conducted sexually transmitted infection testing. The primary outcome was PrEP initiation and the secondary outcome was PrEP persistence at 1 month, determined by pharmacy dispensation records.
resultsOf 386 AGYW screened, 353 were randomized (DST n = 172, control n = 181) with a median age of 21 years (interquartile range [IQR] 20, 23) and 56% (199/353) attending the clinic for HIV testing, 46% (164/353) using contraception, 15% (53/353) using condoms consistently and 37% (108/353) with a curable sexually transmitted infection. PrEP was initiated by 97% in the DST group and 94% in the control group (OR 1.79; 95% confidence interval, CI = 0.79-1.53), of whom two-thirds planned to continue PrEP until they decided if they liked PrEP. At 1 month, PrEP persistence was 19% in the DST and 10% in the control group (OR 1.97, 95% CI 1.08-3.69). Ninety-nine percent randomized to the DST reported satisfaction with MyPrEP.
conclusionsAmong AGYW attending a South African PHC clinic, PrEP uptake was >90% with two-fold higher PrEP persistence at 1 month in those randomized to use the MyPrEP DST. Given the need for strategies to support PrEP implementation and improve low PrEP persistence among African AGYW, a PrEP DST warrants further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.